More about

Etanercept

News
June 18, 2020
2 min read
Save

Combining etanercept, methotrexate improves psoriasis in psoriatic arthritis

Combining etanercept, methotrexate improves psoriasis in psoriatic arthritis

Etanercept monotherapy or a combination of etanercept and methotrexate had better psoriasis outcomes than methotrexate alone, according to a poster presented at the American Academy of Dermatology virtual meeting.

News
March 23, 2020
2 min read
Save

Etanercept may have utility in psoriasis among patients with inadequate apremilast response

Among patients with psoriasis who showed an inadequate response to apremilast, etanercept was associated with strong response rates and patient-reported outcomes, according to a recently published study.

News
November 11, 2019
2 min read
Save

Live zoster vaccine safe, effective in patients taking TNF inhibitors

Live zoster vaccine safe, effective in patients taking TNF inhibitors

ATLANTA — Data from the Varicella Zoster Vaccine study demonstrate that administering live, attenuated varicella vaccine to patients taking TNF inhibitors did not result in any safety events or disease flare after 6 weeks. In addition, there were no cases of varicella infection — either wild or vaccine type.

News
November 10, 2019
3 min read
Save

Price increases doubled public spending on biologic DMARDs

Price increases doubled public spending on biologic DMARDs

ATLANTA — Annual public spending by Medicare and Medicaid on biologic DMARDs more than doubled, from $5.3 billion in 2012 to $10.3 billion in 2016, largely due to post-market price increases, according to Natalie McCormick, PhD, of Massachusetts General Hospital and Harvard Medical School.

News
November 01, 2019
2 min read
Save

Metabolic syndrome confers limited effect at week 28 on PASI response with Ilumya

Metabolic syndrome status numerically affected the median Psoriasis Area and Severity Index score changes in patients receiving Ilumya 100 mg or 200 mg or Enbrel but was not clinically lower, according to research presented at the Academy of Managed Care Pharmacy Nexus.

News
October 31, 2019
2 min read
Save

Ilumya may reduce overall psoriasis treatment costs

Ilumya is among the most cost-effective first-line therapies for treating psoriasis, according to research presented by Justin Carrico, MD, of RTI Health Solutions, and colleagues at Academy of Managed Care Pharmacy Nexus.

News
September 12, 2019
3 min read
Save

Patients with low-disease RA on tofacitinib, methotrexate can safely withdraw methotrexate

Patients with low-disease RA on tofacitinib, methotrexate can safely withdraw methotrexate

Patients with rheumatoid arthritis who achieve low disease activity with tofacitinib plus methotrexate can safely withdraw methotrexate without fear of worsening disease activity, according to findings published in The Lancet Rheumatology.

News
August 28, 2019
2 min read
Save

Some patients prescribed biologics also receive topical medications for psoriasis

Some patients prescribed biologics also receive topical medications for psoriasis

In patients with psoriasis, the median time between first and last biologic prescriptions was between 3.3 and 7 months with up to 50% of patients not prescribed a second prescription for the medication, according to researchers in Journal of Drugs in Dermatology.

News
August 26, 2019
1 min read
Save

Amgen to acquire Otezla, pending Celgene merger

Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

News
August 23, 2019
3 min read
Save

Court ruling upholds Enbrel patent claim, blocks biosimilar rivals

Court ruling upholds Enbrel patent claim, blocks biosimilar rivals

A U.S. District Court judge has ruled in favor of Amgen in its lawsuit against Novartis’ Sandoz, which claimed patent infringement on its biologic etanercept by the biosimilar, etanercept-szzs.

View more